

## **PRESS RELEASE (No. 12)**

**24th November, 2016**

Baar Switzerland and Belgrade, Serbia

### **Amicus S.A. announces signature of a Distribution Agreement to represent Grifols International in Western Balkans and Baltic states.**

On November 22nd, 2016 Amicus S.A. of Baar, Switzerland, and Grifols (comprising Instituto Grifols, Grifols Therapeutics and Grifols Worldwide Operations Ltd.) of Barcelona, Spain signed a long term distribution contract for Grifols' Bioscience Division products. The agreement provides that Amicus S.A. and its affiliates will represent Grifols' plasma-derived products in the Baltics states of Estonia, Latvia and Lithuania) Montenegro and Serbia effective immediately, in Bosnia & Herzegovina and Slovenia effective January 1, 2017 and in Kosovo effective June 1<sup>st</sup>, 2017. Amicus will provide services including distribution, marketing and promotion, market access, pricing, medical affairs, regulatory and pharmacovigilance.

"This agreement marks a significant departure for Amicus," commented Amicus co-founder Petr Nemeč. "First, Grifols is a top-tier, research-based specialty company which has asked us to take on a good-sized existing business with strong prospects for growth. Second, as the agreement covers most of Amicus' current territories and contemplates the two companies registering and launching many new products, it is highly strategic for us. Third, this alliance takes Amicus into the fast-growing specialty area of plasma derivatives, which are being used across many therapeutic areas in which Amicus is currently active, making the business opportunity synergistic. We are delighted to be chosen by Grifols, and thank them for this expression of confidence in Amicus' competencies."

Amicus CEO Jean-Michel Lespinasse echoed Nemeč, commenting that Amicus was "honoured to be selected by such a dynamic company as Grifols, with its leading global positions in IVIG, Alpha-1s, pdFVllls and Albumins. We are privileged to work with a company not only dedicated to research and product innovation, but also which is expanding its production capacity and is committed to self-sufficiency in plasma supply. This is a winning combination for long-term Central Europe plasma derivative market penetration."

#### **About Grifols**

Grifols is a global healthcare company which produces life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care. The company has three primary divisions -- Bioscience, Diagnostic and Hospital – which develop, produce and market innovative products and services to medical professionals in more than 90 countries around the world. For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

#### **About Amicus S.A.**

Amicus subsidiaries operate in the West Balkan and Baltic countries. Set up in 2014, Amicus has gathered outstanding pharmaceutical talent, Medical Devices and also OTC / consumer healthcare. The company specializes in representing research-based pharmaceutical, medical equipment and brand self-care brands. For more info about Amicus, please visit: [www.amicuspharma.eu](http://www.amicuspharma.eu)

#### **Contact:**

**Maja Boskovic, Public Affairs Officer, Amicus**

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321